Blueprint Medicines Lands $40,000,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=da01941f-0ed2-4b42-8e59-ab1172041e41&Preview=1 - Date
4/11/2011 - Company Name
Blueprint Medicines - Mailing Address
Undisclosed Cambridge, MA 02138 - Company Description
Blueprint Medicines is driving the development of personalized, highly-selective cancer therapies that harness the growing understanding of the molecular blueprint of cancer. - Website
http://www.blueprintmedicines.com - Transaction Type
Venture Equity - Transaction Amount
$40,000,000 - Transaction Round
Series A - Proceeds Purposes
Proceeds from the financing will be used to develop new cancer therapies – using the company’s proprietary compound library and Insights-to-Validation™ Platform – that target the driver molecular aberrations of cancer and emerging resistance mechanisms unique to certain cancer patients. - M&A Terms
- Venture Investor
Third Rock Ventures - Venture Investor
Third Rock Ventures - Venture Investor
Undisclosed
